Joshua P Scallan1, Michael A Hill2, Michael J Davis3. 1. Department of Medical Pharmacology and Physiology, University of Missouri, One Hospital Drive, MA415 Medical Sciences Building, Columbia, MO, USA. 2. Department of Medical Pharmacology and Physiology, University of Missouri, One Hospital Drive, MA415 Medical Sciences Building, Columbia, MO, USA Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA. 3. Department of Medical Pharmacology and Physiology, University of Missouri, One Hospital Drive, MA415 Medical Sciences Building, Columbia, MO, USA davismj@health.missouri.edu.
Abstract
AIMS: Lymphatic vessel dysfunction is an emerging component of metabolic diseases and can lead to tissue lipid accumulation, dyslipidaemia, and oedema. While lymph leakage has been implicated in obesity and hypercholesterolaemia, whether similar lymphatic dysfunction exists in diabetes has not been investigated. METHODS AND RESULTS: To measure the lymphatic integrity of transgenic mice, we developed a new assay that quantifies the solute permeability of murine collecting lymphatic vessels. Compared with age-matched wild-type (WT) controls, the permeability of collecting lymphatics from diabetic, leptin receptor-deficient (db/db) mice was elevated >130-fold. Augmenting nitric oxide (NO) production by suffusion of l-arginine rescued this defect. Using pharmacological tools and eNOS(-/-) mice, we found that NO increased WT lymphatic permeability, but reduced db/db lymphatic permeability. These conflicting actions of NO were reconciled by the finding that phosphodiesterase 3 (PDE3), normally inhibited by NO signalling, was active in db/db lymphatics and inhibition of this enzyme restored barrier function. CONCLUSION: In conclusion, we identified the first lymphatic vascular defect in type 2 diabetes, an enhanced permeability caused by low NO bioavailability. Further, this demonstrates that PDE3 inhibition is required to maintain lymphatic vessel integrity and represents a viable therapeutic target for lymphatic endothelial dysfunction in metabolic disease. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Lymphatic vessel dysfunction is an emerging component of metabolic diseases and can lead to tissue lipid accumulation, dyslipidaemia, and oedema. While lymph leakage has been implicated in obesity and hypercholesterolaemia, whether similar lymphatic dysfunction exists in diabetes has not been investigated. METHODS AND RESULTS: To measure the lymphatic integrity of transgenic mice, we developed a new assay that quantifies the solute permeability of murine collecting lymphatic vessels. Compared with age-matched wild-type (WT) controls, the permeability of collecting lymphatics from diabetic, leptin receptor-deficient (db/db) mice was elevated >130-fold. Augmenting nitric oxide (NO) production by suffusion of l-arginine rescued this defect. Using pharmacological tools and eNOS(-/-) mice, we found that NO increased WT lymphatic permeability, but reduced db/db lymphatic permeability. These conflicting actions of NO were reconciled by the finding that phosphodiesterase 3 (PDE3), normally inhibited by NO signalling, was active in db/db lymphatics and inhibition of this enzyme restored barrier function. CONCLUSION: In conclusion, we identified the first lymphatic vascular defect in type 2 diabetes, an enhanced permeability caused by low NO bioavailability. Further, this demonstrates that PDE3 inhibition is required to maintain lymphatic vessel integrity and represents a viable therapeutic target for lymphatic endothelial dysfunction in metabolic disease. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Ying Yang; José Manuel García-Verdugo; Mario Soriano-Navarro; R Sathish Srinivasan; Joshua P Scallan; Manvendra K Singh; Jonathan A Epstein; Guillermo Oliver Journal: Blood Date: 2012-08-02 Impact factor: 22.113
Authors: Catherine Martel; Wenjun Li; Brian Fulp; Andrew M Platt; Emmanuel L Gautier; Marit Westerterp; Robert Bittman; Alan R Tall; Shu-Hsia Chen; Michael J Thomas; Daniel Kreisel; Melody A Swartz; Mary G Sorci-Thomas; Gwendalyn J Randolph Journal: J Clin Invest Date: 2013-03-25 Impact factor: 14.808
Authors: Rachel J Roth Flach; Marina T DiStefano; Laura V Danai; Ozlem Senol-Cosar; Joseph C Yawe; Mark Kelly; Lorena Garcia Menendez; Michael P Czech Journal: Am J Physiol Endocrinol Metab Date: 2017-06-13 Impact factor: 4.310
Authors: Echoe M Bouta; Richard D Bell; Homaira Rahimi; Lianping Xing; Ronald W Wood; Clifton O Bingham; Christopher T Ritchlin; Edward M Schwarz Journal: Nat Rev Rheumatol Date: 2018-01-11 Impact factor: 20.543
Authors: Stoyan Ivanov; Joshua P Scallan; Ki-Wook Kim; Kathrin Werth; Michael W Johnson; Brian T Saunders; Peter L Wang; Emma L Kuan; Adam C Straub; Melissa Ouhachi; Erica G Weinstein; Jesse W Williams; Carlos Briseño; Marco Colonna; Brant E Isakson; Emmanuel L Gautier; Reinhold Förster; Michael J Davis; Bernd H Zinselmeyer; Gwendalyn J Randolph Journal: J Clin Invest Date: 2016-03-21 Impact factor: 14.808
Authors: Matthew D Nitti; Geoffrey E Hespe; Raghu P Kataru; Gabriela D García Nores; Ira L Savetsky; Jeremy S Torrisi; Jason C Gardenier; Andrew J Dannenberg; Babak J Mehrara Journal: J Physiol Date: 2016-10-09 Impact factor: 5.182